Artelo Biosciences Announces Proposed Underwritten Public Offering [Yahoo! Finance]
Artelo Biosciences, Inc. (ARTL)
US:NASDAQ Investor Relations:
artelobio.com/investors
Company Research
Source: Yahoo! Finance
SOLANA BEACH, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced it has commenced an underwritten public offering of its common stock and/or pre-funded warrants. All shares of common stock and/or pre-funded warrants in the offering are to be offered by the Company. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. R.F. Lafferty & Co., Inc. is acting as the sole book-running manager for the offering. The shares of common stock and/or pre-funded warrants are being offered by the Company pursuant to a “shelf” registration statement on Form S-3 (File No. 333-273153), which was filed with the U.S. Securities and Exchange Comm
Show less
Read more
Impact Snapshot
Event Time:
ARTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARTL alerts
High impacting Artelo Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
ARTL
News
- Artelo Biosciences Announces Publication of New Peer-Reviewed Study Demonstrating Intraperitoneal Administration of a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor Significantly Reduces Stress-Induced Anxiety and Depression Behaviors in PreclinicalGlobeNewswire
- Artelo Biosciences (NASDAQ:ARTL) had its "hold" rating reaffirmed by analysts at Maxim Group.MarketBeat
- Artelo Biosciences (NASDAQ:ARTL) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial ResultsGlobeNewswire
ARTL
Sec Filings
- 12/3/25 - Form EFFECT
- 11/25/25 - Form 8-K
- 11/17/25 - Form 3
- ARTL's page on the SEC website